RESUMEN
OBJECTIVE: Evaluation of the efficacy and safety of the drug Acatinol Memantine, 20 mg (once daily) in comparison with the drug Acatinol Memantine, 10 mg (twice daily) in patients with moderate to moderate severe vascular dementia. MATERIAL AND METHODS: The study included 130 patients aged 50-85 years of both sexes with instrumentally and clinically confirmed vascular dementia. The patients were randomized into 2 groups. Group I consisted of 65 patients receiving Akatinol Memantine, 20 mg once daily, group II - 65 patients receiving Akatinol Memantine, 10 mg twice daily for 24 weeks. Clinical, parametric and statistical research methods were used. The Alzheimer's disease assessment scale, the cognitive subscale (ADAS-cog), the short mental Status Assessment Scale (MMSE) and the general clinical impression scale for patients condition and illness severity (CGI-C and CGI-S) and the Hamilton Depression Rating scale (HAM-D) were used. Adverse events were collected and analyzed. RESULTS: At week 24, both groups showed statistically significant positive change in ADAS-cog total score: in group I the total score was 27.2±8.76 points (absolute difference from baseline 3.5 points; p<0.01), and in group II - 26.1±7.86 points (absolute difference from baseline 2.5 points; p<0.01) with no statistically significant differences between groups. Evaluation of secondary efficacy criteria (change in ADAS-cog total score at week 12 and MMSE at weeks 4, 12, and 24) also revealed statistically significant benefit in both groups compared to baseline with no significant differences between groups. Statistically significant improvement was noticed on CGI-S and CGI-C scales in both groups. Akatinol Memantine was safe and well tolerated in both groups. CONCLUSION: The study showed no lesser efficacy and safety of Akatinol Memantine, 20 mg (once daily) compared to Akatinol Memantine, 10 mg (twice daily) in patients with moderate and moderately severe vascular dementia.
Asunto(s)
Enfermedad de Alzheimer , Demencia Vascular , Femenino , Humanos , Masculino , Actividades Cotidianas , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/psicología , Cognición , Demencia Vascular/tratamiento farmacológico , Método Doble Ciego , Memantina/efectos adversos , Resultado del Tratamiento , Persona de Mediana Edad , Anciano , Anciano de 80 o más AñosRESUMEN
Neurodegenerative and cerebrovascular diseases are the most significant among the main reasons leading to the cognitive impairment of the elderly. Vascular cognitive impairment is not limited to only dementia, representing a heterogeneous group both in pathogenic and clinical terms. The article dwells upon new principles of vascular cognitive impairment's classification and the review of their possible therapeutic correction that was conducted. The article includes the results of the 12-week open therapeutic (randomized with the control group) study of efficiency and safety of vitrum memory for patients with mild vascular cognitive impairment. It is shown that the therapy significantly improved the state of neurodynamic and regulatory functions of the patients with I--II stage dyscirculatory encephalopathy.
Asunto(s)
Isquemia Encefálica/complicaciones , Cognición/fisiología , Disfunción Cognitiva/tratamiento farmacológico , Ginkgo biloba , Fitoterapia/métodos , Preparaciones de Plantas/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/fisiopatología , Enfermedad Crónica , Cognición/efectos de los fármacos , Disfunción Cognitiva/etiología , Disfunción Cognitiva/fisiopatología , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Humanos , Masculino , Memoria/efectos de los fármacos , Memoria/fisiología , Persona de Mediana Edad , Preparaciones de Plantas/administración & dosificación , Resultado del TratamientoRESUMEN
The physiometric parameters (exercise performance, muscle strength, and lung capacity) were monitored in schoolchildren over the 15-year period. There has been a reduction in exercise performance, muscle strength and an increase in lung capacity in the past 15 years, which the pediatricians should take into account to detect physical development abnormalities in schoolchildren.
Asunto(s)
Conducta Infantil/psicología , Desarrollo Infantil/fisiología , Psicometría , Somatotipos/psicología , Adolescente , Niño , Femenino , Humanos , Masculino , Estudios RetrospectivosRESUMEN
The study was conducted in 3 Russian centers (Moscow, St. Petersburg and Nizhniy Novgorod). The total sample included 110 patients whose mental state met the definition of <
Asunto(s)
Enfermedad de Alzheimer/prevención & control , Aminoácidos/administración & dosificación , Trastornos del Conocimiento/tratamiento farmacológico , Fármacos Neuroprotectores/administración & dosificación , Alcaloides de la Vinca/administración & dosificación , Administración Oral , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/fisiopatología , Cognición/efectos de los fármacos , Trastornos del Conocimiento/complicaciones , Trastornos del Conocimiento/fisiopatología , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Síndrome , Factores de Tiempo , Resultado del TratamientoRESUMEN
An open comparison study included 29 patients, aged 33-62 years, with chronic pain syndromes of the spine during at least 6 months. A main group (14 patients) received antidepressant cymbalta, an inhibitor of serotonin and noradrenalin reuptake, as an add-on drug. Data of general somatic and neurologic examination, depression level on the Beck Depression Inventory, pain intensity on the Visual Analogous Scale (VAS) were assessed on days 1, 7 and 42. Dynamics of patient's state and tolerability of the drug were assessed separately by a physician and a patient using a special questionnaire. The level of depression was significantly decreased (p<0,01) in the main group to the 42nd day. The intensity of pain syndrome on VAS was significantly lower compare to the control group to the 7th (p<0,05) and 42nd (p<0,01) days. The physician reported the marked improvement in 58% of patients of main group and in 14% of the control one. The improvement assessed by patients was found in 36% of patients of main group and in 7% of patients of control group. Side effects: nausea (28%), dry mouth (21%), constipations (14%), vertigo (21%), sleepiness (14%) were assessed by all but one patient as mild.
Asunto(s)
Antidepresivos/uso terapéutico , Depresión/tratamiento farmacológico , Dolor/tratamiento farmacológico , Tiofenos/uso terapéutico , Adulto , Antidepresivos/administración & dosificación , Enfermedad Crónica , Depresión/etiología , Depresión/fisiopatología , Clorhidrato de Duloxetina , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Dolor/complicaciones , Dolor/fisiopatología , Dimensión del Dolor , Síndrome , Tiofenos/administración & dosificación , Resultado del TratamientoRESUMEN
A potential of prolonged 2-years course of cerebrolysin therapy with courses repeated every 6 months to slow down or prevent the transition of the syndrome of mild cognitive impairment, amnestic type, to clinically relevant dementia has been studied in the open comparative study of 73 patients divided into 2 groups, one of which included patients treated with cerebrolysin and another one those who did not receive this drug. The effect of the 2-years course therapy with cerebrolysin suggested by the authors has been proven. Such therapy allows to prevent the progression of cognitive deficit and development of dementia of Alzheimer's type. The results obtained give grounds to recommend this course therapy for prevention of dementia in elderly patients with mild cognitive impairment.
Asunto(s)
Enfermedad de Alzheimer/prevención & control , Aminoácidos/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/genética , Aminoácidos/administración & dosificación , Apolipoproteínas E/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fármacos Neuroprotectores/administración & dosificación , Pruebas Neuropsicológicas , Índice de Severidad de la EnfermedadRESUMEN
Retrospective and prospective studies were made in 1248 infants of the first year of life and in 642 children aged 7 to 14 years who lived in Kirov and its region. The purpose of the study was to evaluate the impact of different types of feeding on their morbidity. The children who had received an artificial feeding were ascertained to be more frequently ill both in their first year of life and at an older age.
Asunto(s)
Métodos de Alimentación/normas , Morbilidad/tendencias , Adolescente , Niño , Desarrollo Infantil , Estado de Salud , Humanos , Lactante , Recién Nacido , Federación de Rusia/epidemiologíaAsunto(s)
Neuropatía Alcohólica/complicaciones , Aminas/uso terapéutico , Analgésicos/uso terapéutico , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Neuralgia/tratamiento farmacológico , Ácido gamma-Aminobutírico/uso terapéutico , Quimioterapia Combinada , Femenino , Gabapentina , Humanos , Masculino , Persona de Mediana Edad , Neuralgia/etiología , Dolor/tratamiento farmacológico , Dolor/etiología , Síndrome , Resultado del TratamientoRESUMEN
Physical development was comparatively assessed in 1238 children of the first year of life who were differently fed. The children living in both the town of Kirov and rural areas of the Kirov Region who were on artificial feeding showed higher weight and height values, but they developed less harmonically than those of the same age who were fed with breast milk.
Asunto(s)
Alimentación con Biberón , Lactancia Materna , Desarrollo Infantil , Factores de Edad , Humanos , Lactante , Recién Nacido , Población Rural , Federación de Rusia , Población UrbanaRESUMEN
Adjuvant endovascular irradiation of blood with He-Ne laser was used in addition to conventional treatment for bacterial asthma. Out of 48 asthmatics, 16 had a mild disease, 21 moderate, 11 severe forms. The course of treatment included 8-10 daily sessions lasting 30 minutes. A marked clinical response was achieved in 41 patients. The cessation of the asphyxia attacks in them allowed discontinuation or reduction of glucocorticoids administration. The duration of the exacerbations became shorter. The irradiation also stimulated the blood antioxidant system.